麦肯锡：2026新兴战略中心：亚洲在未来生物制药中的作用研究报告（英文版）（16页）.pdf

1、January 2026Life Sciences PracticeThe emerging epicenter:Asias role in biopharmas future The emerging epicenter:Asias role in biopharmas future is published by McKinseys Life Sciences Practice.McKinsey&Company 1200 19th Street NW Fl.10-11,Suite 1100 Washington,DC 20036 Authors:Anirudh Roy Popli,

2、Fangning Zhang,Jay Park,and Franck De Leu Editors:Gwyn Herbein,Imprint Art director:Aphra Communications:Aeri YeoThis publication is not intended to be used as the basis for trading in the shares of any company or for undertaking any other complex or significant financial transaction without consult

3、ing appropriate professional advisers.No part of this publication may be copied or redistributed in any form without the prior written consent of McKinsey&Company.Copyright 2026 McKinsey&Company.All rights reserved.2The emerging epicenter:Asias role in biopharmas future 1.Introduction Asia h

4、as leapfrogged from fast follower to front-runner.Once seen as a manufacturing hub,its now a launchpad for next-gen therapies,new modalities,and global partnerships.That momentum is playing out across key innovation metricsfrom US Food and Drug Administration(FDA)approvals to cross-border deals.Cons

5、ider these milestones:In 2024,Asia generated nearly two-thirds of biotech patent grantsfive times Europes shareand contributed about a quarter of global out-licensing deals.2 While still accounting for only around one in ten FDA novel-drug approvals,these lagging indicators are expected to follow th

6、e regions rapid gains in earlier stages of innovation.Asias emergence as a hub for biopharma innovation is underpinned by government support,deep scientific capabilities,and globalized models of trial design,licensing,and collaboration.Within Asia,China stands out as the pacesetter,now representing